Increased serum levels of interleukin‐23 circulating in patients with non‐segmental generalized vitiligo
Mario Vaccaro, Serafinella Patrizia Cannavò, Selene Imbesi, Mariateresa Cristani, Olga Barbuzza, Valeria Tigano, Sebastiano Gangemi
Abstract
Mario Vaccaro, Serafinella Patrizia Cannavò, Selene Imbesi, Mariateresa Cristani, Olga Barbuzza, Valeria Tigano, Sebastiano Gangemi
Abstract
INTRODUCTION: Vitiligo is a common progressive depigmentation of the skin due to selective destruction of melanocytes. Nowadays increasing evidences support the hypothesis of an autoimmune etiology. METHODS: In order to sustain the role of T-helper-17 lymphocytes in the pathogenesis of vitiligo, we measured the serum levels of interleukin (IL)-23 (an important regulator of this subset) using a quantitative enzyme immunoassay technique in 12 males and 16 females (ages ranging from 18 to 58 years) affected by non-segmental vitiligo and compared the results with a group of healthy donors. RESULTS: IL-23 serum levels were significantly higher in patients with vitiligo as compared with controls. There was a significant positive correlation of IL-23 serum levels with disease duration and extent of vitiligo and disease activity. CONCLUSIONS: The inhibition of IL-23 might be a novel strategy in the therapy of autoimmune inflammatory diseases like vitiligo.
OpenAlex reports 56 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
INTRODUCTION: Vitiligo is a common progressive depigmentation of the skin due to selective destruction of melanocytes. Nowadays increasing evidences support the hypothesis of an autoimmune etiology. METHODS: In order to sustain the role of T-helper-17 lymphocytes in the pathogenesis of vitiligo, we measured the serum levels of interleukin (IL)-23 (an important regulator of this subset) using a quantitative enzyme immunoassay technique in 12 males and 16 females (ages ranging from 18 to 58 years) affected by non-segmental vitiligo and compared the results with a group of healthy donors. RESULTS: IL-23 serum levels were significantly higher in patients with vitiligo as compared with controls. There was a significant positive correlation of IL-23 serum levels with disease duration and extent of vitiligo and disease activity. CONCLUSIONS: The inhibition of IL-23 might be a novel strategy in the therapy of autoimmune inflammatory diseases like vitiligo.
Key concepts: Vitiligo, Medicine, Depigmentation, Pathogenesis, Etiology, Immunology, Autoimmune disease, Disease